Product Pipeline

Clinical Data and
Scientific Presentations

Cutting-edge research advancing our understanding of targeted therapies and cancer immunotherapies.
 

Clinical Data and Scientific Presentations

Tucatinib (ONT-380)

A Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib (ONT-380) vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated HER2+ Unresectable Locally Advanced or Metastatic Breast Carcinoma (HER2CLIMB)

San Antonio Breast Cancer Symposium, December 2016. Program OT1-02-09

Download Poster » 417KB


Efficacy Results of a Phase 1b Study of Tucatinib (ONT-380), an Oral HER2-Specific Inhibitor, in Combination With Capecitabine and Trastuzumab in HER2+ Metastatic Breast Cancer, Including Patients with Brain Metastases

San Antonio Breast Cancer Symposium, December 2016. Abstract P4-21-01

Download Poster » 533KB


Cutaneous Responses in HER2+ Metastatic Breast Cancer in Phase 1b Study of Tucatinib (ONT-380), an Oral HER2 Specific Inhibitor in Combination with Capecitabine and/or Trastuzumab in Third Line or Later Treatment

European Society of Medical Oncology (ESMO) 2016 Congress. Poster 278

Download Poster » 720KB


A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study of Tucatinib (ONT-380) vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated HER2+ Unresectable Locally Advanced or Metastatic Breast Carcinoma

European Society of Medical Oncology (ESMO) 2016 Congress. Poster 312

Download Poster » 116KB


Efficacy results of a phase 1b study of ONT-380, a CNS-penetrant TKI, in combination with T-DM1 in HER2+ metastatic breast cancer (MBC), including patients (pts) with brain metastases.

American Society of Clinical Oncology Annual Meeting, June 2016. Abstract 513

Download Poster » 223KB


A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with ado trastuzumab emtansine (T DM1), in HER2+ metastatic breast cancer (MBC)

San Antonio Breast Cancer Symposium, December 2015. Abstract P4-14-20

Download Poster » 207KB


ONT-380 in the treatment of HER2+ breast cancer central nervous system (CNS) metastases (mets)

San Antonio Breast Cancer Symposium, December 2015. Abstract P4-14-20

Download Poster » 1.48MB


A Phase 1b Study of ONT-380, an Oral HER2-Specific Inhibitor, in Combination with Capecitabine (C) and Trastuzumab (T) in 3rd line+ Treatment of HER2+ Metastatic Breast Cancer (MBC)

American Society of Clinical Oncology Annual Meeting, May 2015. Abstract 602

Download Poster » 357KB


ONT-380 in the Treatment of HER2+ Breast Cancer Central Nervous System (CNS) Metastases (Mets)

American Society of Clinical Oncology Annual Meeting, May 2015. Abstract 612

Download Poster » 625KB


A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with ado-trastuzumab emtansine (T-DM1), in HER2+ metastatic breast cancer (MBC)

American Society of Clinical Oncology Annual Meeting, June 2014. Abstract TPS662

Download Poster » 310KB


A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with ado-trastuzumab (T-DM1), in HER2+ metastatic breast cancer (MBC)

San Antonio Breast Cancer Symposium, December 2014. Poster P5-15-08

Download Poster » 641KB


A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with ado-trastuzumab emtansine (T-DM1), in HER2+ metastatic breast cancer (MBC)

American Society of Clinical Oncology Annual Meeting, June 2014. Abstract TPS662

Download Poster » 310KB


A phase 1b study of ONT-380, an oral ONT HER2-specific inhibitor, combined with capecitabine and trastuzumab, in HER2+ metastatic breast cancer (MBC)

American Society of Clinical Oncology Annual Meeting, June 2014. Abstract TPS663

Download Poster » 494KB


ONT-380 (ARRY-380) - An Oral HER2 Inhibitor - Final Phase 1 Results and Conclusions

American Association for Cancer Research Special Conference on Advances in Breast Cancer Research, October, 2013

Download Poster » 1.31MB

Earlier posters regarding ONT-380 (ARRY-380) can be found on Array Biopharma's website »


Checkpoint Kinase 1

Discovery and development of orally available sub-nanomolar potent checkpoint kinase 1 inhibitors as potential anti-cancer therapies

American Association for Cancer Research Annual Meeting, April 2016. Abstract #2721.

Download Poster » 804KB